Gallien Yves, Martin Adrien, Caserio-Schönemann Céline, Le Strat Yann, Thiam Marie Michèle
Data Science Division, Santé publique France, Saint-Maurice, France
SBIM, APHP, Paris, France.
BMJ Open. 2020 Oct 30;10(10):e037425. doi: 10.1136/bmjopen-2020-037425.
OBJECTIVES: Opioid consumption in France has remained stable over the last 15 years, with much lower levels than in the USA. However, few data are available on patients who consume opioids and their use of the health system. Emergency department (ED) data has never been used as a source to investigate opioid use disorder (OUD) in France. DESIGN/SETTINGS/PARTICIPANTS: We used the OSCOUR national surveillance network, collecting daily ED data from 93% of French ED, to select and describe visits and hospitalisations after an OUD-related ED visit between 2010 and 2018 using International Classification of Diseases, version 10 (ICD10) codes. We described the population of interest and used binomial negative regressions to identify factors significantly associated with OUD such as gender, age, administrative region, year of admission and ICD10 codes. We also analysed the related diagnoses. PRIMARY OUTCOME MEASURE: Trend in ED visits for an OUD-related ED visit. RESULTS: We recorded 34 362 OUD-related visits out of 97 892 863 ED visits (36.1/100 000 visits). OUD-related visits decreased from 39.2/100 000 visits in 2010 to 32.9/100 000 visits in 2018, resulting in an average yearly decrease of 2.1% (95% CI 1.5% to 2.7%) after multivariate analysis. We recorded 15 966 OUD-related hospitalisations out of 20 359 574 hospitalisations after ED visits (78.4/100 000 hospitalisations) with an increase from 74.0/100 000 hospitalisations in 2010 to 81.4/100 000 hospitalisations in 2018. The analysis of related diagnoses demonstrated mostly polydrug abuse in this population. CONCLUSIONS: While the proportion of OUD visits decreased in the time frame, the hospitalisation proportion increased. The implementation of a nationwide surveillance system for OUD in France using ED visits would provide prompt detection of changes over time.
目的:在过去15年里,法国的阿片类药物消费量一直保持稳定,且远低于美国。然而,关于使用阿片类药物的患者及其医疗系统使用情况的数据却很少。在法国,急诊室(ED)数据从未被用作调查阿片类药物使用障碍(OUD)的来源。 设计/地点/参与者:我们使用了OSCOUR国家监测网络,该网络收集了法国93%急诊室的每日ED数据,以使用国际疾病分类第10版(ICD10)编码来选择和描述2010年至2018年期间与OUD相关的急诊就诊后的就诊和住院情况。我们描述了感兴趣的人群,并使用二项式负回归来确定与OUD显著相关的因素,如性别、年龄、行政区、入院年份和ICD10编码。我们还分析了相关诊断。 主要结局指标:与OUD相关的急诊就诊的急诊就诊趋势。 结果:在97892863次急诊就诊中,我们记录了34362次与OUD相关的就诊(每100000次就诊中有36.1次)。与OUD相关的就诊从2010年的每100000次就诊39.2次降至2018年的每100000次就诊32.9次,多变量分析后平均每年下降2.1%(95%CI 1.5%至2.7%)。在急诊就诊后的20359574次住院中,我们记录了15966次与OUD相关的住院(每100000次住院中有78.4次),从2010年的每100000次住院74.0次增加到2018年的每100000次住院81.4次。对相关诊断的分析表明,该人群中大多存在多药滥用情况。 结论:在该时间段内,虽然与OUD相关的就诊比例下降,但住院比例上升。利用急诊就诊情况在法国实施全国性的OUD监测系统将能及时发现随时间的变化。
J Subst Abuse Treat. 2021-8
J Subst Abuse Treat. 2022-11
J Subst Use Addict Treat. 2024-1
JAMA. 2019-2-26
MMWR Morb Mortal Wkly Rep. 2018-1-4
Health Promot Chronic Dis Prev Can. 2018-6
MMWR Morb Mortal Wkly Rep. 2016-12-30